This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Opdivo
  • /
  • Study of Nivolumab Plus Ipilimumab, Ipilimumab or ...
Clinical trial

Study of Nivolumab Plus Ipilimumab, Ipilimumab or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650)

Read time: 3 mins
Last updated:17th Mar 2017
Identifier: NCT02985957

The purpose of this study is to determine whether Nivolumab plus Ipilimumab has preliminary evidence of safety and effectiveness in the treatment of participants with metastatic castration-resistant prostate cancer who have progressed after prior Docetaxel-containing regimen.


Study Type: Interventional  (Clinical Trial)
Estimated Enrollment: 618 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 2 Trial of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer
Actual Study Start Date: March 17, 2017
Estimated Primary Completion Date: June 28, 2021
Estimated Study Completion Date: May 30, 2022

Arms:
- Experimental:
Cohort A (Arm A)
- Experimental: Cohort B (Arm B)
- Experimental: Cohort C (Arm C)
- Experimental: Cohort D (Arm D1)
- Experimental: Cohort D (Arm D2)
- Experimental: Cohort D (Arm D3)
- Experimental: Cohort D (Arm D4)

Category Value
Date last updated at source 2019-11-06
Study type(s) Interventional
Expected enrolment 618
Study start date 2017-03-17
Estimated primary completion date 2021-06-28

View full details